Preclinical studies showed a reduced invasion and metastatic activity in mice with pancreatic NEN treated with CBZ: in particular, the simultaneous inhibition of VEGFR and MET pathways resulted in a smaller tumour mass and no metastases for CBZ-treated mice, compared to only anti-VEGF-treated mice [78]. Here, MET is linked to neoplasm.